Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy
Unlike conventional antibodies, heavy chain only antibodies derived from camel contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Cloned and isolated VHHs possess unique properties that enable them to excel conventional therapeutic antibodies and their smaller antigen-bin...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tabriz University of Medical Sciences
2013-01-01
|
Series: | BioImpacts |
Subjects: | |
Online Access: | http://dx.doi.org/10.5681/bi.2013.009 |
id |
doaj-6a2128123cb24bdf99d1affe48a2c4fb |
---|---|
record_format |
Article |
spelling |
doaj-6a2128123cb24bdf99d1affe48a2c4fb2020-11-24T20:41:46ZengTabriz University of Medical SciencesBioImpacts2228-56522228-56602013-01-013114Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer TherapySeyed Moein MoghimiFatemeh RahbarizadehDavoud AhmadvandLadan ParhamifarUnlike conventional antibodies, heavy chain only antibodies derived from camel contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Cloned and isolated VHHs possess unique properties that enable them to excel conventional therapeutic antibodies and their smaller antigen-binding fragments in cancer targeting and therapy. VHHs express low immunogenicity, are highly robust and easy to manufacture and have the ability to recognize hidden or uncommon epitopes. We highlight the utility of VHH in design of new molecular, multifunctional particulate and immune cell-based systems for combating HER2+ breast cancer.http://dx.doi.org/10.5681/bi.2013.009Chimeric Antigen ReceptorsHeavy Chain Only AntibodiesHER2NanotechnologySingle Variable Domain |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Seyed Moein Moghimi Fatemeh Rahbarizadeh Davoud Ahmadvand Ladan Parhamifar |
spellingShingle |
Seyed Moein Moghimi Fatemeh Rahbarizadeh Davoud Ahmadvand Ladan Parhamifar Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy BioImpacts Chimeric Antigen Receptors Heavy Chain Only Antibodies HER2 Nanotechnology Single Variable Domain |
author_facet |
Seyed Moein Moghimi Fatemeh Rahbarizadeh Davoud Ahmadvand Ladan Parhamifar |
author_sort |
Seyed Moein Moghimi |
title |
Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy |
title_short |
Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy |
title_full |
Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy |
title_fullStr |
Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy |
title_full_unstemmed |
Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy |
title_sort |
heavy chain only antibodies: a new paradigm in personalized her2+ breast cancer therapy |
publisher |
Tabriz University of Medical Sciences |
series |
BioImpacts |
issn |
2228-5652 2228-5660 |
publishDate |
2013-01-01 |
description |
Unlike conventional antibodies, heavy chain only antibodies derived from camel contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Cloned and isolated VHHs possess unique properties that enable them to excel conventional therapeutic antibodies and their smaller antigen-binding fragments in cancer targeting and therapy. VHHs express low immunogenicity, are highly robust and easy to manufacture and have the ability to recognize hidden or uncommon epitopes. We highlight the utility of VHH in design of new molecular, multifunctional particulate and immune cell-based systems for combating HER2+ breast cancer. |
topic |
Chimeric Antigen Receptors Heavy Chain Only Antibodies HER2 Nanotechnology Single Variable Domain |
url |
http://dx.doi.org/10.5681/bi.2013.009 |
work_keys_str_mv |
AT seyedmoeinmoghimi heavychainonlyantibodiesanewparadigminpersonalizedher2breastcancertherapy AT fatemehrahbarizadeh heavychainonlyantibodiesanewparadigminpersonalizedher2breastcancertherapy AT davoudahmadvand heavychainonlyantibodiesanewparadigminpersonalizedher2breastcancertherapy AT ladanparhamifar heavychainonlyantibodiesanewparadigminpersonalizedher2breastcancertherapy |
_version_ |
1716823868175286272 |